{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43","upperLimit":"98","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"HIV-positive patients treated with 2 cycles of ABVD followed by response-adapted therapy. Initial ABVD: Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 2 cycles. Interim PET-negative patients continue with 4 cycles of ABVD: Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 4 cycles. Interim PET-positive patients receive 6 cycles of standard BEACOPP: Etoposide 100 mg/m\\^2 IV Days 1, 2, 3, Doxorubicin 25 mg/m\\^2 IV Day 1, Cyclophosphamide 650 mg/m\\^2 IV Day 1, Procarbzine 100 mg/m\\^2 PO Days 1-7, Prednisone 40 mg/m\\^2 PO Days 1-14, Bleomycin 10u/m\\^2 IV Day 8, Vincristine 1.4 mg/m\\^2 IV Day 8, Q 21 Days x 6 cycles","id":"OG000","title":"HIV-positive: 2 Cycles of ABVD Followed by PET-directed Therap"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable HIV-positive patients who started initial ABVD were included in the analysis regardless the response-adapted therapy after 2 initial cycles of ABVD was administered.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.","type":"SECONDARY","unitOfMeasure":"percentage of participants"}